Alpha-1-antitrypsin deficiency is based on a common genetic disorder. The disease manifests itself in the lungs in the form of chronic obstructive bronchitis with pulmonary emphysema (COPD), as well as in the liver in the form of chronic hepatitis, developing into cirrhosis of the liver. The disease is diagnosed via the regulation of the alpha-1-antitrypsin concentration in the serum. All patients with chronic respiratory problems, which may indicate illness, should be tested for alpha-1-antitrypsin deficiency. Treatment options for lung capacity consist of anti-obstructive and anti-inflammatory treatments. Replacement therapy can also be added to the range of treatments available. The aim of the treatments is to slow the rapid decline in lung capacity. In the advanced stages, a lung or liver transplant might be necessary. Liver transplantation is curative, because alpha-1-antitrypsin is hardly present in the extrahepatic material, but it does not repair existing lung damage. The website of our alpha-1 patient organisation in Bern, Switzerland, can be found under: www.alpha-1.ch . There you can read all available information and use it how you wish.